Complexities in the development of cyclin-dependent kinase inhibitor drugs

Trends in Molecular Medicine

Volumn 8, Issue 4 SUPPL., 2002, Pages

  Sausville, Edward A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CELL CYCLE; DRUG MECHANISM; HUMAN; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; HUMANS; NEOPLASMS;

EID: 0036220822     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)02308-0     Document Type: Review

References (54)

1. Principles of CDK regulation
2. The regulation of E2F by pRB-family proteins
3. The G2-phase DNA-damage checkpoint
4. CDK inhibitors: Positive and negative regulators of G1-phase progression
5. Preclinical and clinical development of cyclin-dependent kinase modulators
6. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
7. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal omain during Human Immunodeficiency Virus Type 1 transcription
8. Temporal regulation of RNA polymerase II by Srb10 and Kin28 cyclin-dependent kinases
9. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro
10. Transcription elongation factor P-TEFb mediate Tat activation of HIV-1 transcription at multiple stages
11. Identification of multiple cyclin subunits of human P-TEFb
12. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase
13. Upregulation of cyclin T1/CDK9 complexes during T cell activation
14. 7SK small nuclear RNA binds to and inhibit the activity of CDK9/cyclin T complexes
15. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription
16. Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25
17. Cyclin-dependent kinase 5 promotes insulin exocytosis
18. Indirubins inhibit glycogen synthase kinase-3β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's Disease
19. Inhibition of CDKs as a therapeutic modality
20. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
21. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol
22. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication
23. Flavopiridol inactiviates P-TEFb and blocks most RNA polymerase II transcription in vivo
24. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol
25. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
26. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis
27. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines
28. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocyctic leukemia
29. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles
30. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: Synthesis and biological effects
31. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): Design, synthesis, enzymatic activities, and X-ray crystallographic analysis
32. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4
33. Identification of selective inhibitors of cyclin dependent kinase 4
34. Cyclin-dependent kinase inhibitors for treating cancer
35. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors
36. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells
37. Prevention of chemotherapy-reduced alopecia in rats by CDK inhibitors
38. Design of new inhibitors for CDC2 kinase based on a multiple pseudosubstrate structure
39. Cyclin-dependent kinases: Engines, clocks, and microprocessors
40. Timing is everything: Regulation of mitotic exit and cytokinesis by the MEN and SIN
41. Specific protection against breast cancers by cyclin D1 ablation
42. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
43. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
44. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway
45. Cdk 10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity
46. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
47. Proteasome inhibitors: A novel class of potent and effective antitumor agents
48. Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2
49. Isolation of the human cdk2 gene that encodes the cyclin A and adenovirus E1A-associated p33 kinase
50. cdc2
51. Molecular cloning and expression of glycogen synthase kinase-3/factor A
52. Homology probing: Identification of cDNA clones encoding members of the protein-serine kinase family
53. A family of human cdc2-related protein kinases
54. PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro